Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. [electronic resource]
Producer: 20191106Description: 417-426 p. digitalISSN:- 1542-7714
- Adult
- Aged
- Aminoisobutyric Acids
- Antiviral Agents -- adverse effects
- Benzimidazoles -- adverse effects
- Cyclopropanes
- Double-Blind Method
- Drug-Related Side Effects and Adverse Reactions -- epidemiology
- Female
- Genotype
- Hepacivirus -- classification
- Hepatitis C, Chronic -- drug therapy
- Humans
- Lactams, Macrocyclic
- Leucine -- analogs & derivatives
- Male
- Middle Aged
- Placebos -- administration & dosage
- Proline -- analogs & derivatives
- Pyrrolidines
- Quinoxalines -- adverse effects
- Sulfonamides -- adverse effects
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.